The GLP-1 Research Landscape in 2026
GLP-1 receptor agonists have become the most intensively studied peptide class in metabolic research. What began as glucose homeostasis research has expanded into cardiovascular outcomes, neuroscience, hepatic steatosis, renal function, and beyond. The volume of published data — from the SUSTAIN, STEP, PIONEER, SELECT, SURPASS, and SURMOUNT trial programs alone — represents one of the largest peptide research datasets in history.
This overview covers the current state of GLP-1 research as of 2026: available compounds, key recent data, regulatory developments, and practical considerations for researchers sourcing these compounds.
Available GLP-1 Research Compounds
Semaglutide (Selective GLP-1R Agonist)
- MW: 4,113.58 Da | CAS: 910463-68-2
- Half-life: ~168 hours (7 days)
- Key modification: C18 fatty diacid for albumin binding
- Trial programs: SUSTAIN (10 trials), STEP (5+), PIONEER (10), SELECT
- Major 2024-2026 data: SELECT cardiovascular outcomes (PMID: 37952131), STEP HFpEF (heart failure with preserved EF), FLOW (renal outcomes)
- BeaCapra: 3 mg, $129.99 ($110.49 subscribe)
Full guide: Semaglutide: The Complete Research Guide 2026
Tirzepatide (Dual GIP/GLP-1R Agonist)
- MW: 4,813.45 Da | CAS: 2023788-19-2
- Half-life: ~120 hours (5 days)
- Key modification: C20 fatty diacid; engineered GLP-1R cross-reactivity from GIP backbone
- Trial programs: SURPASS (8 trials), SURMOUNT (4+)
- Major 2024-2026 data: SURMOUNT-3 (sequential lifestyle + pharmacotherapy), SURMOUNT-4 (withdrawal/regain), SURPASS-CVOT (cardiovascular outcomes, ongoing)
- BeaCapra: 5 mg, $149.99 ($127.49 subscribe)
Full guide: Tirzepatide Research Guide
Key Research Developments (2024-2026)
Cardiovascular Outcomes Beyond Diabetes
The SELECT trial (PMID: 37952131) demonstrated that semaglutide reduced major adverse cardiovascular events by 20% in subjects with established cardiovascular disease without diabetes — expanding the research relevance of GLP-1R agonists beyond metabolic disease. This was the first demonstration of cardiovascular benefit with any GLP-1R agonist in a non-diabetic population, and it has reshaped the research agenda around GLP-1R's role in atherosclerosis, vascular inflammation, and cardiac metabolism.
Heart Failure Research
The STEP-HFpEF trial demonstrated significant improvements in heart failure symptoms, exercise capacity, and body weight in subjects with obesity-related heart failure with preserved ejection fraction (HFpEF). This has opened a new research domain at the intersection of metabolic and cardiovascular biology.
Renal Outcomes
The FLOW trial evaluated semaglutide's effects on kidney function in subjects with type 2 diabetes and chronic kidney disease. Results demonstrated a significant reduction in the composite kidney outcome, adding nephroprotection to the expanding list of GLP-1R-mediated effects under investigation.
Hepatic Steatosis (MASH/NAFLD)
Multiple studies have demonstrated that GLP-1R agonists reduce hepatic fat content, improve liver enzymes, and may reduce fibrosis progression in metabolic dysfunction-associated steatohepatitis (MASH). This has become one of the most active areas of GLP-1 research, with dedicated trials ongoing for both semaglutide and tirzepatide.
Neurological Research
GLP-1R expression in the brain extends beyond appetite regulation. Research is investigating GLP-1R agonists in the context of neurodegenerative diseases, with preclinical data suggesting neuroprotective effects through anti-inflammatory and neurotrophic mechanisms. Clinical trials are evaluating semaglutide in Alzheimer's disease (EVOKE trial program).
Oral Formulations
The PIONEER program demonstrated that oral semaglutide (co-formulated with the absorption enhancer SNAC) can achieve therapeutic exposures via oral delivery. Research into oral GLP-1 formulations continues, with implications for route-of-administration studies and bioavailability research.
The Dual Agonist Frontier
Tirzepatide's success as a dual GIP/GLP-1R agonist has catalyzed interest in multi-receptor incretin agonism. The research community is now investigating:
- Triple agonists (GIP/GLP-1/glucagon): Compounds like retatrutide that add glucagon receptor agonism to the dual incretin mechanism, potentially enhancing energy expenditure and hepatic fat reduction
- GIP-R biology: Renewed interest in GIP-R pharmacology, which was previously underappreciated relative to GLP-1R
- Receptor selectivity studies: Understanding how the ratio of GIP-R vs GLP-1R activation influences efficacy and tolerability profiles
- Combination approaches: Investigating synergies between incretin agonism and other metabolic targets (SGLT2 inhibition, FGF21, amylin analogs)
Sourcing Considerations for 2026
Purity Standards
As GLP-1 research matures, analytical standards are tightening. Leading suppliers now maintain ≥99% HPLC purity floors (versus the historical ≥95-98% that was common). Batch-specific COAs with both HPLC and mass spectrometry confirmation are becoming the expected standard for credible research.
Supply Chain Reliability
The surge in GLP-1 research demand has created periodic supply constraints across the industry. Researchers running long-term protocols should consider suppliers with automated delivery programs that prioritize subscriber fulfillment. BeaCapra's subscribe & save program — the only one in the research peptide industry — was designed specifically for this need.
Regulatory Awareness
Researchers should be aware of the evolving regulatory landscape around GLP-1 compounds. All research-grade peptides must be sold strictly for research use only (RUO), with clear labeling as "not for human consumption." Suppliers making therapeutic claims or marketing products for self-administration are operating outside legitimate research supply channels.
BeaCapra's GLP-1 Portfolio
| Compound | Target | Size | Price | Subscribe |
|---|---|---|---|---|
| Semaglutide | GLP-1R | 3 mg | $129.99 | $110.49 (15% off) |
| Tirzepatide | GIP-R + GLP-1R | 5 mg | $149.99 | $127.49 (15% off) |
Both compounds ship with batch-specific COAs, same-day (before 2PM EST), with free shipping over $149. Explore all compounds in our GLP-1 Research Hub.
Frequently Asked Questions
What are the most studied GLP-1 peptides?
Semaglutide and tirzepatide are the most extensively studied GLP-1 compounds, with combined clinical trial data from over 50,000 subjects across the SUSTAIN, STEP, PIONEER, SELECT, SURPASS, and SURMOUNT programs.
Is GLP-1 research still growing in 2026?
Yes. GLP-1 research has expanded from metabolic disease into cardiovascular outcomes, heart failure, kidney disease, liver disease, and neuroscience. The field is growing faster than at any point in its history.
What's the difference between semaglutide and tirzepatide?
Semaglutide selectively targets GLP-1R; tirzepatide targets both GIP-R and GLP-1R. See our detailed comparison.
Where should I source GLP-1 peptides for research?
Look for suppliers providing ≥99% HPLC purity, batch-specific COAs with MS confirmation, and reliable delivery. BeaCapra is the only supplier offering subscription delivery for research peptides. See our sourcing guide.
Can I get GLP-1 peptides on subscription?
Only from BeaCapra. Our subscribe & save program provides 15% off with automated delivery every 30, 60, or 90 days on both semaglutide and tirzepatide.
All BeaCapra products are sold for research use only. Not for human consumption.